For the year ending 2025-12-31, PTGX had $31,203K increase in cash & cash equivalents over the period. $56,081K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenue | 46,016 |
| Discovery department expense (excluding employee wages and benefits, stock-based compensation and expense allocations) | 21,822 |
| Development department expense (excluding employee wages and benefits, stock-based compensation and expense allocations) | 65,987 |
| General and administrative expenses (excluding employee wages and benefits, stock-based compensation and expense allocations) | 23,401 |
| Employee wages and benefits - discovery | 9,879 |
| Employee wages and benefits - development | 21,392 |
| Employee wages and benefits - general and administrative | 15,688 |
| Stock-based compensation expense | 45,974 |
| Other segment items | -27 |
| Interest income | 28,789 |
| Income tax expense | 838 |
| Net (loss) income | -130,149 |
| Stock-based compensation | 45,974 |
| Non-cash lease expense | 1,588 |
| Depreciation | 1,280 |
| Accretion of discount on marketable securities | 7,223 |
| Other | -8 |
| Receivable from collaboration partner | -164,879 |
| Prepaid expenses and other assets | 2,360 |
| Accounts payable | 3,723 |
| Accrued expenses and other payables | 4,576 |
| Deferred revenue | -21,017 |
| Income taxes payable | -2,689 |
| Operating lease liability | 903 |
| Net cash provided by (used in) operating activities | 57,671 |
| Purchase of marketable securities | 546,585 |
| Proceeds from maturities of marketable securities | 491,840 |
| Proceeds from sale of marketable securities | 7,003 |
| Purchases of property and equipment | 1,590 |
| Net cash used in investing activities | -49,332 |
| Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan | 23,343 |
| Tax withholding payments related to net settlement of restricted stock units | 479 |
| Net cash provided by financing activities | 22,864 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 31,203 |
| Cash, cash equivalents and restricted cash, beginning of period | 97,474 |
| Cash, cash equivalents and restricted cash, end of period | 128,677 |
Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc (PTGX)